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Abstract
Background: There is emerging evidence showing a significant relationship between overall survival (OS) in
non-small cell lung cancer NSCLC patients and weight change during chemotherapy or chemoradiation. A
high neutrophil/lymphocyte ratio (NLR) at baseline and at follow-up is associated with shorter survival in cancer
patients and may be a surrogate for ongoing inflammation, implicated in cancer cachexia and tumor progression.
The objective of this study is to explore potential relationships between OS, serial weights, and serial NLRs in
advanced NSCLC patients receiving chemotherapy.
Methods: One hundred thirty-nine patients with chemotherapy-naïve NSCLC, predominantly with stage III/IV disease,
were treated with first-line platinum doublets from June, 2011 to August, 2012. NLR, tumor response, and body weight
were recorded at baseline, 6, and 12 weeks from initiation of therapy and correlated with OS. The association between
NLR and OS was assessed using Cox PH (proportional hazards) analysis, the association between NLR and weight
change was assessed using a simple regression analysis, and the association between NLR and tumor response was
assessed using the Fisher’s exact test.
Results: One hundred thirty-nine patients with median age 68, PS 0-1/2 = 83/17%, male/female = 58%/42%. Median
NLR at baseline was 3.6 (range 0.1898 to 30.910), at 6 weeks 3.11 (range 0.2703 to 42.11), and at 12 weeks 3.52
(range 0.2147 to 42.93). A Higher NLR at baseline, 6, and 12 weeks was associated with decreased OS (baseline:
HR 1.06, p < 0.001; 6 weeks: HR 1.07, p = 0.001; 12 weeks: HR 1.05, p < 0.001), and longitudinal NLR, as a time-dependent
covariate, was also associated with decreased OS (HR = 1.06, p < 0.001). Baseline weight and NLR were inversely related
(cor = −0.267, p = 0.001), and weight change and NLR were inversely related at 12 weeks (cor = −0.371, p < 0.001).
Longitudinal measurements of weight and NLR were also negatively associated (slope = −0.06, p < 0.001). Using a
cutoff of NLR > 5, there was a significant association between progressive disease and NLR > 5 at 6 weeks (p = 0.02)
and 12 weeks (p = 0.03).
Conclusions: High baseline and progressive increases in NLRs are associated with progressive disease, inferior OS
and weight loss in NSCLC patients. In addition to having prognostic significance, these observations suggest that
studying molecular mediators of cachexia/inflammation and their relationships to tumor progression may identify
new therapeutic targets in the large subset of NSCLC patients who have cancer cachexia.
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Background
Cancer cachexia represents a multifactorial spectrum of
disease that has been defined by international consensus
as “an ongoing loss of skeletal muscle mass (with or
without loss of fat mass) that cannot be fully reversed by
conventional nutritional support and leads to progressive
functional impairment” [1]. Prevalence rates of cachexia
differ by malignancy type, with approximately 60% of
NSCLC patients experiencing it [2]. Cancer cachexia
may be a result of both reduced nutritional intake and
increased resting energy expenditure [3]. More recent
evidence suggests that there are several other factors
that contribute to cancer cachexia, which includes in-
creased insulin resistance, hypogonadism, adrenergic ac-
tivation, and activation of proinflammatory responses
[4]. Identifying and combating this phenomenon has
taken on great importance in light of studies showing
that weight change in advanced NSCLC patients receiving
concurrent chemoradiation or chemotherapy alone is
inversely associated with overall survival (OS) [5–7].
Similarly, loss of muscle mass (regardless of BMI) is also
associated with worse functional status and OS [8].
The NLR is the ratio between the neutrophil and
lymphocyte counts; what constitutes an elevated value
varies between >3.5 and >5. Several studies have already
shown that an increased baseline NLR is associated
with poor clinical outcomes for several types of cancers,
including NSCLC [9–13]. There is relatively little infor-
mation regarding longitudinal NLRs, which some have
posited may be even more predictive of individual
patient outcomes [14] and may be a dynamic indicator
of tumor status, cachexia, and ongoing inflammation.
Our objective was to investigate potential relationships
between longitudinal NLRs, body weights, and overall
survival.
Methods
One hundred thirty-nine patients with NSCLC who were
treated with first-line platinum doublets from June, 2011
to August, 2012 were reviewed for this study; none of
the patients received prior therapy with an EGFR tyro-
sine kinase inhibitor. 127 patients had stage III or stage
IV NSCLC, and 12 patients had either stage I or stage II
disease and received adjuvant chemotherapy following
surgical resection. This study was approved by the insti-
tutional review board, and compliant with the Helsinki
declaration. NLR and body weight were recorded at
baseline, 6, and 12 weeks from initiation of therapy and
correlated with OS. All patients had blood drawn in out-
patient clinic on the day of evaluation and treatment for
advanced NSCLC. None had active infections at the time
of these visits. Neutrophil and lymphocyte counts were
measured on the Sysmex XN-9000 Hematology Analyzer,
Sysmex Corporation, Kobe, Japan. Albumin was measured
on the Architect Clinical Chemistry Analyzer C16000,
Abbott Diagnostics, Santa Clara, California. The associ-
ation of OS at NLR at baseline, 6 weeks, and 12 weeks
was assessed using the Kaplan-Meier method, the log-
rank test, and the Cox proportional hazards (PH) ana-
lysis. The effect of serial NLR measured longitudinally
on OS was assessed using a time-dependent covariate
Cox PH analysis. The longitudinal association between
weight and NLR was measured serially at baseline, 6 and
12 weeks was assessed using a mixed effects longitudinal
analysis. The association between NLR and tumor re-
sponse was assessed using a Fisher’s exact test. Tumor
response rates were calculated for the patients with
measurable disease according to the RECIST (Response
Evaluation Criteria in Solid Tumors) 1.1 guidelines. The
ALI index was defined as the BMI*Albumin/NLR, and
ALI was calculated at baseline, 6 and 12 weeks from
initiation of therapy and correlated with OS; 96, 93,
and 84 patients had ALI scores available at baseline, 6
and 12 weeks respectively.
Results
Of 139 patients evaluated, the median age was 68 years,
and 58% were male. 83% had a performance score of 0–
1 and 17% had a performance score of 2 (Table 1).
The median NLR at baseline (Table 2) was 3.6 (range
0.1898 to 30.910), at 6 weeks 3.11 (range 0.2703 to
42.11), and at 12 weeks 3.52 (range 0.2147 to 42.93).
Higher NLR at baseline, 6 and 12 weeks were associated
with decreased OS (baseline: HR 1.06, p < 0.001; 6 weeks:
HR 1.07, p = 0.001; 12 weeks: HR 1.05, p < 0.001). When
the serial measurements of NLR measured longitudinally
at baseline, 6 and 12 weeks are considered as a time-
dependent covariate, a Cox PH analysis continued to
support its strongly significant association with decreased
OS (HR = 1.06, p < 0.001).
NLR > 3.5 and NLR > 5 have both been used to define
the elevated NLR group [15]. As shown in Fig. 1, there
were strongly significant differences in OS between the
elevated (>3.5) and non-elevated (≤3.5) NLR groups at
baseline (NLR ≤ 3.5 group median OS not reached vs.
NLR >3.5 group median OS 11.6 months, p = 0.003), at
6 weeks (median OS not reached vs 11.4 mos, p = 0.001)
and at 12 weeks (median OS not reached vs 11.6 mos,
p = 0.001). The same held true when using an NLR cut-
off of 5. The median OS in the non-elevated (≤5) NLR
group at baseline, 6 weeks, and 12 weeks were not
reached; the median OS in the elevated (>5) NLR group
at baseline was 9.08 months, at 6 weeks was 11 months,
and at 12 weeks was 11 months (p ≤ 0.009).
Baseline weight and baseline NLR were negatively
correlated (cor = −0.267, p = 0.001), and the change in
weight from baseline to 12 weeks and 12 week-NLR
were also inversely related (cor = −0.371, p < 0.001). The
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serial measurements of weight and NLR were found to be
significantly associated in a longitudinal mixed effects re-
gression analysis (slope = −0.06, p < 0.001).
The range of weight change was −13.17 kg to +16.61 kg
(median −0.5 kg, mean −0.89 kg) over 12 weeks from initi-
ation of chemotherapy. 55 patients experienced weight
gain ≥ +0.1 kg at 12 weeks; of that group, 41 patients
exhibited weight gain at 6 weeks. Of the 55 patients
who gained weight at 12 weeks, the median weight gain
was +2.41 kg. 73 patients lost weight at 12 weeks, and
the median weight loss was −3.08 kg (Table 3). 37
patients gained albumin at 12 weeks; of that group, 25
patients had gained albumin at 6 weeks. The median
albumin gain was +0.4 g/dL. 40 patients had a decrease
in albumin at 12 weeks, with a median loss of −0.2 g/dL.
20 patients had no change in their albumin (Table 3). Al-
though there is variability amongst individual patients,
there is a longitudinal inverse relationship between NLR
and weight change (cor −0.06224, p < 0.001). There was
no observed association between weight change and al-
bumin change at 6 or 12 weeks (p = 0.265).
In addition, of the 96 patients who had a baseline ALI
score available (Table 4), 38 (39.5%) patients had a base-
line ALI < 18 with median OS of 9.6 months compared
to the 58 patients with ALI ≥ 18 with median OS not
reached (p = 0.001). Of 93 patients who had a 6 week
ALI score available, 41 (44%) had an ALI < 18 with me-
dian OS 11.4 months compared to the 52 patients with
ALI >18 with median OS not reached (p = 0.03). Of the
84 patients who had a 12 week ALI score available, 30
(35.7%) had an ALI < 18 with median OS of 9 months
compared to the 54 patients with ALI ≥ 18 with median
OS not reached (p < 0.001).
Tumor response was calculated at both 6 and 12-
week intervals. In total, there were 85 patients for
whom a 6-week response was measurable and 95 pa-
tients for whom a 12-week response was measurable.
Response data were not available for 54 patients at the
6-week time point and for 44 patients at the 12-week
time point because they had evaluable disease only
based on RECIST 1.1 response criteria or a CT scan
was not performed at that time point. Using a cutoff of
NLR > 5, there was a significant association between
progressive disease and NLR > 5 at 6 weeks (p = 0.02)
and at 12 weeks (p = 0.03). With a cutoff of NLR > 3.5,
there was a significant association between progressive
disease and NLR >3.5 at 6 weeks (p = 0.02), with a trend
toward significance at 12 weeks (p = 0.06).
Discussion
Our understanding of the relationship between cancer
cachexia, inflammation, and survival in NSCLC continues
to evolve. Pretreatment ALI (BMI*Albumin/NLR) has
been one attempt to bridge these three concepts, and was
Table 1 Demographics












Smoking History At Diagnosis (n, %)
Current Smoker 56 (40.3%)
Former Smoker 72 (51.8%)
Never Smoker 11 (7.91%)
Stage at Diagnosis (n, %)
Stage Ia 2 (1.4%)
Stage IIa 10 (7.2%)
Stage III 54 (38.9%)




Squamous Cell 42 (30.2%)
Large Cell 2 (1.4%)
Other 3 (2.2%)






aReceived adjuvant chemotherapy following surgical resection
Table 2 Neutrophil-to-Lymphocyte Ratios at Baseline, 6 Weeks &
12 Weeks
Interval Change in NLR (n, %) Median NLR Range
Baseline – 3.6 0.1898 – 30.910
6 Weeks Increase (63, 45.6%) 3.11 0.2703 – 42.11
Decrease (75, 54.4%)
N/A (1)
12 Weeks Increase (67, 51.9%) 3.52 0.2147 – 42.93
Decrease (62, 48.1%)
N/A (10)
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Fig. 1 Kaplan Meier Survival Plots by NLR. Kaplan Meier survival plots were generated using an NLR cutoff of 3.5 at baseline (a), at 6 weeks (b),
and at 12 weeks (c) and an NLR cutoff of 5 at baseline (d), at 6 weeks (e), and at 12 weeks (f). A significant difference in overall survival was seen
in all three categories, illustrating that an NLR > 3.5 and an NLR > 5 serve as poor prognostic factors associated with worse overall survival at
diagnosis and during chemotherapy
Table 3 Changes in Weight and Albumin at 6 & 12 Weeks
Weight Change at 6 Weeks (n) Weight Change at 12 Weeks (n) Median Weight Change at 12 Weeks
Increase (55) Increase (55) +2.41 kg
Decrease (80) Decrease (73) −3.08 kg
No change (4) No change (1) 0 kg
N/A (10)
Albumin Change at 6 Weeks (n) Albumin Change at 12 Weeks (n) Median Albumin Change at 12 Weeks
Increase (36) Increase (37) +0.4 g/dl
Decrease (59) Decrease (40) −0.2 g/dl
No Change No Change (20) 0 g/dl
N/A (44) N/A (42)
No. Maintained Weight Gain from Weeks 6 to 12 41/55 (74.5%)
No. Maintained Albumin Gain from Weeks 6 to 12 25/37 (67.6%)
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shown to be an independent marker of poor outcome in
patients with advanced NSCLC when the ALI < 18 com-
pared to ALI ≥ 18 [16]. Those patients had more sites of
metastatic disease, and poorer PFS (2.4 vs. 5.1 months,
p < 0.001) and OS (3.4 vs. 8.3 months, p < 0.001). Our
findings here confirm that a pretreatment ALI < 18 is as-
sociated with poorer OS in advanced stage NSCLC.
Tumor markers such as carcinoembryonic antigen
(CEA), cancer antigen 125 (CA-125), and squamous
cell carcinoma (SCC) antigen have been used to assist
in diagnosis and prognosis in lung cancer but are not
definitive [17, 18]. The advantage of using the NLR
alone as a longitudinal prognostic marker is in its ease
of use. The ability to use a single calculation to estimate
survival, derived only from a complete blood count
with differential, is attractive. A recent meta-analysis
demonstrated that an elevated NLR is associated with
shorter progression free and overall survival in both
NSCLC and SCLC, though the authors note the study
was limited by bias in publication, selection, and het-
erogeneity [19]. Another meta-analysis found that the
NLR had consistent prognostic value for overall sur-
vival in NSCLC with a cutoff value of 5 [20]. In patients
receiving first-line epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs), the data are
heterogeneous. While one study showed that an elevated
NLR ≥ 3.5 was associated with poor outcomes in EGFR-
mutated advanced NSCLC [15], another has shown that
NLR did not affect survival in EGFR-mutated advanced
NSCLC [21].
The data presented here not only shows that higher
baseline NLRs are associated with inferior OS, but that
progressive increases in NLR during treatment also por-
tend a worse prognosis. Importantly, longitudinal NLRs
are inversely related to both overall survival and serial
body weights. Thus, the NLR has the potential for prog-
nostication throughout a patient’s treatment course. This
is confirmed by the evidence that shows a significant
association between progressive disease and NLR > 5 at
both 6 and 12 weeks following therapy initiation. These
findings suggest that patients with higher systemic in-
flammation at diagnosis may have more aggressive dis-
ease and should be treated promptly and potently, while
an increasing NLR during treatment may be a harbinger
of disease progression and treatment failure.
Our findings are in line with evidence suggesting the
role of neutrophils in modulating the cancer milieu.
Neutrophils have the ability to suppress antitumor im-
munity, promote tumor cell proliferation, and enhance
tumor cell survival, all which serve to promote tumor
growth. Aging neutrophils are phagocytosed by macro-
phages, which have the ability to increase vascular perme-
ability that enables tumor cell intravasation and metastasis
[22]. Supporting the potential specific association between
NLR and survival in NSCLC are studies in animal models
with a STK11/LKB1-inactivating mutation. Inactivation of
this tumor suppressor gene led to significant increases in
tumor-promoting cytokines and neutrophils with T-cell
suppressive effects. Interestingly, when an IL-6 antibody
was introduced to the murine model, the mice experi-
enced both a significant decrease in tumor-associated
neutrophils and a significant improvement in survival
compared to the control mice [23].
Conclusions
It is likely that NLR is a surrogate for ongoing inflamma-
tion, and that inflammation may be a linchpin that links
tumor progression with cachexia and overall survival.
While previous studies have shown the prognostic value
of baseline NLR, it has been suggested that longitudinal
NLRs may be more informative for individual patients
[14]. The negative correlation between longitudinal NLRs,
overall survival, and body weights observed in our patients
suggests that simply measuring longitudinal NLRs may
provide important prognostic information and may serve
as a real-time indicator of disease progression and the
degree of inflammation occurring in individual NSCLC
patients. If this observation is confirmed in larger studies,
it could have important implications for developing treat-
ments for cancer cachexia and for designing combinations
of immune modulators.
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